Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses
- 23 June 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 15 (7), 11180-11191
- https://doi.org/10.1021/acsnano.1c03972
Abstract
Studies of two SARS-CoV-2 mRNA vaccines suggested that they yield similar to 95% protection from symptomatic infection at least short-term, but important clinical questions remain. It is unclear how vaccine-induced antibody levels quantitatively compare to the wide spectrum induced by natural SARS-CoV-2 infection. Vaccine response kinetics and magnitudes in persons with prior COVID-19 compared to virus-naive persons are not well-defined. The relative stability of vaccineinduced versus infection-induced antibody levels is unclear. We addressed these issues with longitudinal assessments of vaccinees with and without prior SARS-CoV-2 infection using quantitative enzyme-linked immunosorbent assay (ELISA) of anti-RBD antibodies. SARS-CoV-2-naive individuals achieved levels similar to mild natural infection after the first vaccination; a second dose generated levels approaching severe natural infection. In persons with prior COVID-19, one dose boosted levels to the high end of severe natural infection even in those who never had robust responses from infection, increasing no further after the second dose. Antiviral neutralizing assessments using a spike-pseudovirus assay revealed that virus-naive vaccinees did not develop physiologic neutralizing potency until the second dose, while previously infected persons exhibited maximal neutralization after one dose. Finally, antibodies from vaccination waned similarly to natural infection, resulting in an average of similar to 90% loss within 90 days. In summary, our findings suggest that two doses are important for quantity and quality of humoral immunity in SARS-CoV-2-naive persons, while a single dose has maximal effects in those with past infection. Antibodies from vaccination wane with kinetics very similar to that seen after mild natural infection; booster vaccinations will likely be required.Funding Information
- AIDS Healthcare Foundation
- National Institute of Allergy and Infectious Diseases (AI028697)
- McCarthy Foundation
- private donors
- Pendleton Trust
This publication has 63 references indexed in Scilit:
- A serological assay to detect SARS-CoV-2 seroconversion in humansNature Medicine, 2020
- Antibody responses to SARS-CoV-2 in patients with COVID-19Nature Medicine, 2020
- Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases, 2020
- SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test SetupCurrent Protocols in Microbiology, 2020
- Consistent Detection of 2019 Novel Coronavirus in SalivaClinical Infectious Diseases, 2020
- The time course of the immune response to experimental coronavirus infection of manEpidemiology and Infection, 1990
- RISES IN TITERS OF ANTIBODY TO HUMAN CORONA VIRUSES OC43 AND 229E IN SEATTLE FAMILIES DURING 1975–1979American Journal of Epidemiology, 1986
- Epidemiology of coronavirus respiratory infections.Archives of Disease in Childhood, 1983
- VIROLOGIC STUDIES OF ACUTE RESPIRATORY DISEASE IN YOUNG ADULTSAmerican Journal of Epidemiology, 1972
- STUDIES ON ANTIBODY PRODUCTIONThe Journal of Experimental Medicine, 1955